FDA’s Creation Of Pharmacologic Classes Is Mostly Reviewers’ Responsibility
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
A new chapter of CDER’s Manual of Policies and Procedures says reviewers should consider pharmacologic class in the IND stage as pharmacology information is submitted.